Klaus Viktor Toyka

Klaus Viktor Toyka's AcademicInfluence.com Rankings

Klaus Viktor Toyka

Medical

#1506

World Rank

#1850

Historical Rank

Neurology

#130

World Rank

#196

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Klaus Viktor Toyka Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Klaus Viktor Toyka's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome (1998) (849)
Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. (1994) (731)
Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. (1997) (648)
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters (2002) (558)
Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome (1997) (542)
Effect of a Novel Free Radical Scavenger, Edaravone (MCI-186), on Acute Brain Infarction (2003) (534)
Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. (2005) (446)
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. (1977) (437)
CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation (2002) (400)
Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice (1995) (369)
Preceding infections, immune factors, and outcome in Guillain–Barré syndrome (2001) (369)
Defective propagation of signals generated by sympathetic nerve stimulation in the liver of connexin32-deficient mice. (1996) (368)
Axonal prion protein is required for peripheral myelin maintenance (2010) (362)
Animal models for autoimmune demyelinating disorders of the nervous system. (2000) (315)
Structural Abnormalities and Deficient Maintenance of Peripheral Nerve Myelin in Mice Lacking the Gap Junction Protein Connexin 32 (1997) (313)
Protein zero (P0)–deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies (1995) (307)
Immunopathogenesis and treatment of the guillain‐barré syndrome—part I (1995) (293)
Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. (2004) (283)
Differential expression of cytokines in painful and painless neuropathies (2007) (276)
Substance P: binding properties and studies on cellular responses in guinea pig macrophages. (1986) (271)
A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis (2000) (269)
Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. (1998) (241)
Mice deficient for the glycoprotein show subtle abnormalities in myelin (1994) (237)
Impaired Differentiation of Schwann Cells in Transgenic Mice with Increased PMP22 Gene Dosage (1996) (236)
Specific Subtypes of Cutaneous Mechanoreceptors Require Neurotrophin-3 Following Peripheral Target Innervation (1996) (234)
Inflammatory mediators in demyelinating disorders of the CNS and PNS (1992) (229)
Autoimmune human T lymphocytes specific for acetylcholine receptor (1984) (224)
Disease progression in amyotrophic lateral sclerosis: Predictors of survival (2002) (223)
A PD‐1 polymorphism is associated with disease progression in multiple sclerosis (2005) (220)
Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations (2008) (218)
Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis (2005) (210)
Production of nitrite by neonatal rat microglial cells/brain macrophages. (1992) (208)
Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis (2000) (206)
Myasthenia gravis (1983) (201)
Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin (2005) (200)
Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM‐1 (1993) (192)
Microglia and macrophages are major sources of locally produced transforming growth factor‐β1 after transient middle cerebral artery occlusion in rats (1998) (191)
Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy (2001) (190)
Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. (1997) (187)
A role for BDNF in mechanosensation (1998) (187)
Neutralizing antibodies to interleukin 1-receptor reduce pain associated behavior in mice with experimental neuropathy (1999) (186)
Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. (2003) (182)
Activation of macrophages by substance P: induction of oxidative burst and thromboxane release. (1983) (182)
Inflammatory infiltrates in sural nerve biopsies in Guillain‐Barré syndrome and chronic inflammatory demyelinating neuropathy (1996) (182)
Etanercept reduces hyperalgesia in experimental painful neuropathy (2001) (181)
The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain‐Barré syndrome and in other neuroimmunological disorders (1993) (178)
Intravenous immunoglobulin for myasthenia gravis. (2003) (174)
Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. (2010) (167)
The Wlds Mutation Delays Robust Loss of Motor and Sensory Axons in a Genetic Model for Myelin-Related Axonopathy (2003) (164)
Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-α, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin (2000) (159)
Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: Correlation with magnetic resonance imaging (1995) (158)
Serum interleukin‐2 concentrations in Guillain‐Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: Comparison with other neurological diseases of presumed immunopathogenesis (1991) (156)
Heterozygous Peripheral Myelin Protein 22-Deficient Mice Are Affected by a Progressive Demyelinating Tomaculous Neuropathy (1997) (156)
Cytokine mRNA expression in patients with multiple sclerosis and fatigue (2004) (156)
Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy (2010) (152)
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. (2002) (151)
Serial Determination of Tumor Necrosis Factor-Alpha Content in Rat Sciatic Nerve after Chronic Constriction Injury (1999) (148)
Diagnostic validity of epidermal nerve fiber densities in painful sensory neuropathies (2008) (148)
The role of macrophages and eicosanoids in the pathogenesis of experimental allergic neuritis. Serial clinical, electrophysiological, biochemical and morphological observations. (1988) (148)
Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis (1995) (147)
Escalating immunotherapy of multiple sclerosis (1999) (146)
Transforming growth factor-β1: A lesion-associated cytokine of the nervous system (1995) (143)
Microglial Phagocytosis of Apoptotic Inflammatory T Cells Leads to Down-Regulation of Microglial Immune Activation1 (2001) (141)
Symptomatic Treatment of Multiple Sclerosis (2006) (141)
Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability (2001) (139)
Different Intracellular Pathomechanisms Produce Diverse Myelin Protein Zero Neuropathies in Transgenic Mice (2006) (137)
Corticosteroids for myasthenia gravis. (2005) (137)
in Vivo Monitoring of Macrophage Infiltration in Experimental Ischemic Brain Lesions by Magnetic Resonance Imaging (2003) (135)
Plasma exchange for myasthenia gravis. (2002) (133)
Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders (2001) (132)
Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. (2006) (130)
High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. (2001) (127)
Intravenous immunoglobulin for myasthenia gravis. (2012) (127)
Assessing grip strength in healthy individuals and patients with immune‐mediated polyneuropathies (2000) (121)
Neuromuscular blockade by IgG antibodies from patients with Guillain‐Barré syndrome: A macro‐patch‐clamp study (1998) (120)
HLA-DQ BETA-CHAIN POLYMORPHISM LINKED TO MYASTHENIA GRAVIS (1986) (120)
Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS‐1) (2007) (119)
Plasma exchange for generalised myasthenia gravis (2002) (119)
Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance. (2000) (118)
T cell activation in Guillain‐Barré syndrome and in MS (1990) (118)
T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. (2000) (117)
Intravenous immunoglobulins neutralize blocking antibodies in Guillain‐Barré syndrome (2002) (117)
Patients with active relapsing‐remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: Implications for remyelination (2000) (116)
Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. (1999) (115)
Production and characterization of monoclonal antibodies to the extracellular domain of P0 (1993) (115)
Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. (2002) (114)
Treatment of gustatory sweating with botulinum toxin (1997) (112)
Fatigue in MS is related to sympathetic vasomotor dysfunction (2003) (112)
The Role of Macrophages in Demyelinating Peripheral Nervous System of Mice Heterozygously Deficient in P0 (2001) (111)
Circulating adhesion molecules and inflammatory mediators in demyelination (1995) (111)
Azathioprine toxicity during long‐term immunosuppression of generalized myasthenia gravis (1988) (110)
Lenticular nucleus lesion in idiopathic dystonia detected by transcranial sonography (1996) (110)
Phagocytosis of apoptotic inflammatory cells by microglia and its therapeutic implications: Termination of CNS autoimmune inflammation and modulation by interferon‐beta (2003) (110)
The role of interferon‐gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system (1990) (109)
Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP (2005) (108)
Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide— mechanisms independent of pyrimidine depletion (2004) (107)
H2O2 and Nitric Oxide‐mediated Oxidative Stress Induce Apoptosis in Rat Skeletal Muscle Myoblasts (1996) (107)
Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis (2006) (106)
In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema. (1996) (105)
Analysis of Varicella-Zoster Virus in Temporal Arteries Biopsy Positive and Negative for Giant Cell Arteritis. (2015) (103)
Autonomic dysfunction in ALS: A preliminary study on the effects of intrathecal BDNF (2005) (102)
Substance P and astrocytes: stimulation of the cyclooxygenase pathway of arachidonic acid metabolism (1988) (102)
Expression of specific matrix metalloproteinases in inflammatory myopathies. (2001) (101)
Myasthenia gravis: Reactivation of clinical disease and of automimmune factors after discontinuation of long‐term azathioprine (1985) (101)
Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. (2000) (100)
Outcome in juvenile-onset myasthenia gravis: a retrospective study with long-term follow-up of 79 patients (1997) (100)
Fatal PML associated with efalizumab therapy (2012) (98)
Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients (2005) (98)
PREDNISONE IN DUCHENNE MUSCULAR DYSTROPHY (1974) (98)
Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. (2002) (96)
Multiple symmetric lipomatosis (1994) (96)
Conduction failure and nerve conduction slowing in experimental allergic neuritis induced by P2‐specific T‐cell lines (1986) (96)
Failure of anti‐GM1 IgG OR IgM to induce conduction block following intraneural transfer (1995) (96)
Pravastatin-associated inflammatory myopathy. (1992) (95)
Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor alpha subunit. (1987) (95)
Pre‐ and postsynaptic blockade of neuromuscular transmission by Miller–Fisher syndrome IgG at mouse motor nerve terminals (1998) (94)
Astrocytes Are Less Efficient in the Removal of Apoptotic Lymphocytes than Microglia Cells: Implications for the Role of Glial Cells in the Inflamed Central Nervous System (2002) (94)
Functional Connectivity under Optogenetic Control Allows Modeling of Human Neuromuscular Disease. (2016) (93)
Myopathy as a first symptom of Huntington's disease in a Marathon runner (2007) (91)
Botulinum toxin for palmar hyperhidrosis (1997) (91)
Muscle pathology in 57 patients with myotonic dystrophy type 2 (2004) (89)
Antigen presentation by astrocytes primes rat T-lymphocytes for apoptotic cell death (1994) (89)
Suppression of experimental autoimmune neuritis by the oxygen radical scavengers superoxide dismutase and catalase (1988) (89)
Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1. (2003) (87)
Nerve growth factor evokes hyperalgesia in mice lacking the low-affinity neurotrophin receptor p75 (1998) (85)
Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. (2006) (85)
Heparin and Air Filters Reduce Embolic Events Caused by Intra-Arterial Cerebral Angiography: A Prospective, Randomized Trial (2004) (84)
Linkage of proximal myotonic myopathy to chromosome 3q (1999) (83)
Soluble ICAM‐1 serum levels in multiple sclerosis and viral encephalitis (1993) (81)
Pharmacokinetics of Intrathecally Applied BDNF and Effects on Spinal Motoneurons (1996) (79)
Recombinant interleukin-1β stimulates eicosanoid production in rat primary culture astrocytes (1989) (77)
A metalloprotease-inhibitor reduces pain associated behavior in mice with experimental neuropathy 1 Presented in part at the Meeting of the Peripheral Nerve Society, Cambridge, UK, July 10, 1997. 1 (1997) (77)
Presence of the terminal complement complex (C5b‐9) precedes myelin degradation in immune‐mediated demyelination of the rat peripheral nervous system (1991) (76)
Immune-mediated components of hereditary demyelinating neuropathies: lessons from animal models and patients (2004) (76)
Human Stiff person syndrome IgG-containing high-titer anti-GAD65 autoantibodies induce motor dysfunction in rats (2013) (76)
Cognitive performance after coronary artery bypass grafting: A follow-up study (2002) (76)
Synergistic Effect of IFN-γ and TNF-α on Expression of Immune Molecules and Antigen Presentation by Schwann Cells (1995) (75)
Sequential expression of chemokines in experimental autoimmune neuritis (2000) (75)
Myeloma neuropathy: passive transfer from man to mouse. (1981) (75)
Production of MMPs in Human Cerebral Endothelial Cells and Their Role in Shedding Adhesion Molecules (2001) (74)
MHC Class l‐Mediated Cytotoxicity Does Not Induce Apoptosis in Muscle Fibers nor in Inflammatory T Cells: Studies in Patients with Polymyositis, Dermatomyositis, and Inclusion Body Myositis (1996) (73)
Escalating immunotherapy of multiple sclerosis--new aspects and practical application. (2004) (73)
Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome (2003) (73)
Immune Mechanisms in Inflammatory Polyneuropathy a (1988) (72)
Expression of neurofilaments and of a titin epitope in thymic epithelial tumors. Implications for the pathogenesis of myasthenia gravis. (1996) (72)
Guillain‐barré syndrome (1987) (71)
Rapid-onset central motor plasticity in multiple sclerosis (2010) (71)
Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies (2003) (70)
An animal model for Charcot-Marie-Tooth disease type 4B1. (2005) (70)
Selective elimination of macrophages by dichlormethylene diphosphonate-containing liposomes suppresses experimental autoimmune neuritis (1993) (70)
Immunopathogenesis and treatment of the guillain–barré syndrome—part II (1995) (69)
Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. (1999) (68)
Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome (2000) (68)
Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate (2004) (68)
Quantification of interleukin-6 mRNA in wallerian degeneration by compétitive reverse transcription polymerase chain reaction (1996) (68)
Immunoglobulin G from a patient with Miller-Fisher syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice (1995) (68)
["Fatigue" in multiple sclerosis. Development and and validation of the "Würzburger Fatigue Inventory for MS"]. (2006) (67)
Suppression of experimental autoimmune neuritis by leflunomide. (2001) (67)
Kinetics and Organ Distribution of IL-17-Producing CD4 Cells in Proteolipid Protein 139–151 Peptide-Induced Experimental Autoimmune Encephalomyelitis of SJL Mice1 (2007) (66)
Prevention and therapy of experimental autoimmune neuritis by an antibody against T cell receptors-alpha/beta. (1992) (66)
Pyridostigmine but not 3,4‐diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle‐specific kinase autoantibody (2013) (66)
Neurological multisystem manifestation in multiple symmetric lipomatosis: A clinical and electrophysiological study (1995) (66)
Activated T cells of nonneural specificity open the blood‐nerve barrier to circulating antibody (1995) (66)
Isolation and characterization of an oligodendrocyte precursor–derived B‐cell epitope in multiple sclerosis (1998) (65)
Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats (1996) (65)
Myasthenia gravis (1986) (63)
The Gdap1 knockout mouse mechanistically links redox control to Charcot–Marie–Tooth disease (2014) (62)
Amphipathic segment of the nicotinic receptor alpha subunit contains epitopes recognized by T lymphocytes in myasthenia gravis. (1988) (62)
Suppression of experimental allergic neuritis by an antibody to the intracellular adhesion molecule ICAM-1. (1993) (62)
Macrophage differentiation antigens in acute and chronic autoimmune polyneuropathies. (1998) (62)
Comparison of maximal voluntary isometric contraction and Drachman's hand‐held dynamometry in evaluating patients with amyotrophic lateral sclerosis (1999) (61)
Mtmr13/Sbf2-deficient mice: an animal model for CMT4B2. (2007) (61)
Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome (2002) (61)
Genetic restriction of autoreactive acetylcholine receptor-specific T lymphocytes in myasthenia gravis. (1985) (60)
Myelin is dependent on the Charcot–Marie–Tooth Type 4H disease culprit protein FRABIN/FGD4 in Schwann cells (2012) (60)
EAE in beta-2 microglobulin-deficient mice: axonal damage is not dependent on MHC-I restricted immune responses (2005) (60)
Neurology's witness to history (1998) (59)
Intravenous Glucocorticosteroid Treatment Augments Apoptosis of Inflammatory T Cells in Experimental Autoimmune Neuritis (EAN) of the Lewis Rat (1995) (58)
Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. (1999) (58)
The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis of the Lewis rat. (1998) (57)
Leukotriene production by cultured astroglial cells (1987) (57)
Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats (1995) (57)
Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP (2003) (57)
Phagocytotic removal of apoptotic, inflammatory lymphocytes in the central nervous system by microglia and its functional implications (2002) (57)
Secretion of nitrite by Schwann cells and its effect on T-cell activation in vitro. (1996) (57)
Early natural course of transient encephalopathy after coronary artery bypass grafting (2000) (55)
"Atraumatic" Sprotte needle reduces the incidence of post-lumbar puncture headaches. (2002) (55)
Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells (2008) (54)
Human Stiff-Person Syndrome IgG Induces Anxious Behavior in Rats (2011) (54)
Immunotherapy in autoimmune neuromuscular disorders (2003) (54)
In vivo monitoring of macrophage infiltration in experimental autoimmune neuritis by magnetic resonance imaging (2004) (54)
Transforming growth factor-beta 1 in experimental autoimmune neuritis. Cellular localization and time course. (1996) (54)
Chronic inflammatory polyneuropathy Reduction of nerve conduction velocities in monkeys by systemic passive transfer of immunoglobulin G (1984) (54)
T-cell receptor (TCR) usage in Lewis rat experimental autoimmune encephalomyelitis: TCR beta-chain-variable-region V beta 8.2-positive T cells are not essential for induction and course of disease. (1995) (53)
Human autoantibodies to amphiphysin induce defective presynaptic vesicle dynamics and composition. (2016) (53)
Gadofluorine M enhancement allows more sensitive detection of inflammatory CNS lesions than T2-w imaging: a quantitative MRI study. (2008) (53)
Phorbol diester TPA elicits prostaglandin E release from cultured rat astrocytes (1987) (53)
Sequential Expression of Transforming Growth Factor‐β1 by T‐cells, Macrophages, and Microglia in Rat Spinal Cord during Autoimmune Inflammation (1998) (52)
Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies (2000) (52)
Macrophages but not schwann cells express ia antigen in experimental autoimmune neuritis (1990) (51)
Mitochondrial dysfunction with myoclonus epilepsy and ragged‐red fibers point mutation in nerve, muscle, and adipose tissue of a patient with multiple isymmetric lipomatosis (1997) (51)
Molecular Mechanisms of High-Dose Antigen Therapy in Experimental Autoimmune Encephalomyelitis: Rapid Induction of Th1-Type Cytokines and Inducible Nitric Oxide Synthase1 (2000) (51)
Mycophenolate Mofetil in the Therapy of Severe Myasthenia gravis (2001) (51)
Genetic variation at position –1082 of the interleukin 10 (IL10) promotor and the outcome of multiple sclerosis (2000) (51)
An Imbalance of Two Functionally and Phenotypically Different Subsets of Plasmacytoid Dendritic Cells Characterizes the Dysfunctional Immune Regulation in Multiple Sclerosis (2010) (51)
Plasma exchange in chronic inflammatory polyneuropathy: Evidence suggestive of a pathogenic humoral factor (1982) (51)
Skin biopsy as an additional diagnostic tool in non-systemic vasculitic neuropathy (2010) (50)
The mouse blood-brain barrier and blood-nerve barrier for IgG: A tracer study by use of the avidin-biotin system (2004) (50)
Anti-ganglioside antibodies alter presynaptic release and calcium influx (2007) (50)
Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis (2002) (50)
Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors (2012) (49)
The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model (2015) (49)
Comparison of transcranial sonography, magnetic resonance imaging, and single photon emission computed tomography findings in idiopathic spasmodic torticollis (1997) (49)
Selective loss of cholinergic sudomotor fibers causes anhidrosis in Ross syndrome (2002) (48)
Transgenic Lewis rats overexpressing the proteolipid protein gene: myelin degeneration and its effect on T cell-mediated experimental autoimmune encephalomyelitis (1999) (48)
Macrophages and endothelial cells express intercellular adhesion molecule-1 in immune-mediated demyelination but not in Wallerian degeneration of the rat peripheral nervous system. (1993) (48)
Modulation of cytokine mRNA expression by brain-derived neurotrophic factor and nerve growth factor in human immune cells (2003) (47)
In situ detection of transforming growth factor-β mRNA in experimental rat glioma and reactive glial cells (1994) (47)
Psychotic Symptoms and Emotional Distress in Patients with Guillain-Barré Syndrome (2002) (47)
The pathogenesis of CIDP (2003) (47)
Magnetic resonance imaging investigation of blood-brain barrier damage in adoptive transfer experimental autoimmune encephalomyelitis (1993) (47)
Non-neural-specific T lymphocytes can orchestrate inflammatory peripheral neuropathy. (1995) (47)
Humoral factors in peripheral nerve disease (1987) (46)
„Fatigue“ bei Multipler Sklerose (2006) (46)
Progressive sudomotor dysfunction in amyotrophic lateral sclerosis (2002) (44)
Spatial diversity of blood–brain barrier alteration and macrophage invasion in experimental autoimmune encephalomyelitis: A comparative MRI study (2009) (44)
Partial inhibition of AT-EAE by an antibody to ICAM-1: Clinico-histological and MRI studies (1996) (44)
Proximal myotonic myopathy (2000) (43)
Antigen therapy eliminates T cell inflammation by apoptosis: effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2. (1997) (43)
The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis (2004) (43)
Immune mechanisms in acquired demyelinating neuropathies: lessons from animal models (2002) (43)
In situ demonstration of T cell activation and elimination in the peripheral nervous system during experimental autoimmune neuritis in the Lewis rat (1996) (43)
Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration (2016) (42)
Human cerebral endothelial cells are a potential source for bioactive BDNF. (2002) (42)
Production of prostanoids by Lewis rat Schwann cells in vitro (1994) (42)
Diagnostic impact of cerebral transit time in the identification of microangiopathy in dementia: A transcranial ultrasound study. (1999) (42)
LONG‐TERM CORRELATION OF CLINICAL COURSE AND ACETYLCHOLINE RECEPTOR ANTIBODY IN PATIENTS WITH MYASTHENIA GRAVIS (1981) (42)
Malignancies after mitoxantrone for multiple sclerosis (2016) (41)
THE PROPERTIES OF UNMYELINATED NOCICEPTIVE AFFERENTS CHANGE IN A PAINFUL CHRONIC CONSTRICTION NEUROPATHY (1994) (41)
Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin (1998) (40)
Primary rat astroglial cultures can generate leukotriene B4 (1988) (40)
Influenza vaccination in MS (2001) (40)
Inhibition of experimental autoimmune neuritis by an antibody to the lymphocyte function-associated antigen-1. (1994) (39)
Non-systemic vasculitic neuropathy: single-center follow-up of 60 patients (2015) (39)
Gene polymorphism at position –308 of the tumor necrosis factor α promotor is not associated with disease progression in multiple sclerosis patients (1999) (38)
Intrathecal, Polyspecific Antiviral Immune Response in Oligoclonal Band Negative Multiple Sclerosis (2012) (38)
Protective role of the cytokine‐inducible isoform of nitric oxide synthase induction and nitrosative stress in experimental autoimmune encephalomyelitis of the DA rat (2003) (38)
Relation of clinical, serological, morphological, and electrophysiological findings in galactocerebroside-induced experimental allergic neuritis. (1986) (38)
Isolated meningeal tuberculoma mimicking meningioma: case report. (1995) (38)
Potential role of LIF as a modifier gene in the pathogenesis of amyotrophic lateral sclerosis (2000) (38)
Passive transfer studies in demyelinating neuropathy with IgM monoclonal antibodies to myelin-associated glycoprotein. (1985) (38)
Lipocortin-1 (annexin-1) suppresses activation of autoimmune T cell lines in the Lewis rat (1996) (37)
Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis (2002) (37)
Substance P, the immune system and inflammation. (1989) (37)
Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor-α (2001) (37)
Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2 (1995) (36)
Atraumatic needle reduces the incidence of post-lumbar puncture syndrome (1994) (36)
[Cellular immunity in inflammatory autoimmune neuropathies] (2002) (36)
Neuroprotective effect of the immune system in a mouse model of severe dysmyelinating hereditary neuropathy: enhanced axonal degeneration following disruption of the RAG-1 gene (2005) (36)
[Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002]. (2002) (35)
Human IgG directed against amphiphysin induces anxiety behavior in a rat model after intrathecal passive transfer (2012) (35)
Chronic inflammatory polyneuritis and related neuropathies (1996) (34)
The PLPp-specific T-cell population promoted by pertussis toxin is characterized by high frequencies of IL-17-producing cells. (2007) (34)
Modulation of experimental autoimmune neuritis in Lewis rats by oral application of myelin antigens (1997) (34)
The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis (2009) (34)
Polyethylene glycol-coupled IGF1 delays motor function defects in a mouse model of spinal muscular atrophy with respiratory distress type 1. (2014) (33)
Increased autophagy in peripheral nerves may protect Wistar Ottawa Karlsburg W rats against neuropathy (2013) (33)
Review: Progress in the treatment of myasthenia gravis (2008) (33)
Apoptotic cell death of T-lymphocytes in experimental autoimmune neuritis of the Lewis rat (1994) (32)
Hereditary defect of cobalamin metabolism (homocystinuria and methylmalonic aciduria) of juvenile onset. (1996) (32)
Tumor necrosis factor-α (TNF) regulates the expression of ICAM-1 predominantly through TNF receptor 1 after chronic constriction injury of mouse sciatic nerve (2002) (32)
Ultrastructural findings in endomyocardial biopsy of patients with Kearns-Sayre syndrome. (1988) (32)
Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human myasthenic IgG. (1980) (32)
Rat astrocytes express interferon-γ immunoreactivity in normal optic nerve and after nerve transection (1990) (31)
Experimental autoimmune encephalomyelitis in mice with a targeted deletion of the inducible nitric oxide synthase gene: increased T-helper 1 response (2004) (31)
Synergistic effect of IFN-gamma and TNF-alpha on expression of immune molecules and antigen presentation by Schwann cells. (1995) (31)
Immune mechanisms in inflammatory polyneuropathy (1987) (30)
Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis (2009) (30)
Effector mechanisms in myasthenia gravis: End‐plate function after passive transfer of IgG, Fab, and F(ab′)2 hybrid molecules (1986) (30)
Pathogenetic Significance of Fetal-Type Acetylcholine Receptors on Thymic Myoid Cells in Myasthenia Gravis (1992) (30)
Bone Marrow Transfer from Wild-Type Mice Reverts the Beneficial Effect of Genetically Mediated Immune Deficiency in Myelin Mutants (2001) (30)
Detection and quantification of antibodies to the extracellular domain of P0 during experimental allergic neuritis (1993) (29)
Meningeal Hyperperfusion Visualized by MRI in a Patient With Visual Hallucinations and Migraine (1996) (29)
Inherited demyelinating neuropathies: from gene to disease. (1998) (29)
Downregulation of Transforming Growth Factor-&bgr;2 Facilitates Inflammation in the Central Nervous System by Reciprocal Astrocyte/Microglia Interactions (2007) (29)
Clinical outcome of sural nerve biopsy: a retrospective study (1999) (29)
IgG from patients with Guillain–Barré syndrome interact with nicotinic acetylcholine receptor channels (2003) (28)
Functional role of ipsilateral motor areas in multiple sclerosis (2010) (28)
Serum levels of soluble E‐selectin (ELAM‐1) in immune‐mediated neuropathies (1994) (27)
Role of TNF‐α in High‐Dose Antigen Therapy in Experimental Autoimmune Neuritis: Inhibition of TNF‐α by Neutralizing Antibodies Reduces T‐Cell Apoptosis and Prevents Liver Necrosis (2000) (27)
Creatine monohydrate in DM2/PROMM (2003) (27)
Myasthenia gravis: further electrophysiological and ultrastructural analysis of transmission failure in the mouse passive transfer model. (1978) (27)
Regulation of Fas and FasL expression on rat Schwann cells. (2000) (26)
Neuromyotonia in mice with hereditary myelinopathies (2000) (26)
Expression of intercellular adhesion molecule-1 on rat microglial cells (1993) (26)
Therapeutic effect of transforming growth factor-beta 2 on actively induced EAN but not adoptive transfer EAN. (1994) (25)
Plasma exchange in polyradiculoneuropathy (1980) (25)
Mafosfamide induces DNA fragmentation and apoptosis in human T-lymphocytes. A possible mechanism of its immunosuppressive action. (1995) (25)
Electrophysiological investigations in adoptively transferred experimental autoimmune encephalomyelitis in the Lewis rat. (1989) (25)
Management of cervical radiculopathy. (1995) (25)
Biphasic form of experimental autoimmune neuritis in dark agouti rats and its oral therapy by antigen‐specific tolerization (2004) (25)
Assessment of cardiovascular autonomic function in myotonic dystrophy type 2 (DM2/PROMM) (2003) (25)
T cell vaccination does not induce resistance to experimental autoimmune neuritis (1991) (25)
Impact of the Asp299Gly polymorphism in the toll-like receptor 4 (tlr-4) gene on disease course of multiple sclerosis (2005) (24)
Autoimmune responses in peripheral nerve (2004) (24)
Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]. (1999) (24)
Dysregulated IGFBP5 expression causes axon degeneration and motoneuron loss in diabetic neuropathy (2015) (24)
Neonatal Guillain-Barré syndrome (1999) (24)
Ciclosporin A prevents P2 T cell line-mediated experimental autoimmune neuritis (AT-EAN) in rat (1987) (23)
Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitope (2001) (23)
Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat (1997) (23)
Propentofylline and iloprost suppress the production of TNF-alpha by macrophages but fail to ameliorate experimental autoimmune encephalomyelitis in Lewis rats. (1997) (23)
Stiff person syndrome associated anti-amphiphysin antibodies reduce GABA associated [Ca2+]i rise in embryonic motoneurons (2009) (23)
Cardiac metabolism and function in patients with multiple sclerosis: a combined 31P-MR-spectroscopy and MRI study. (2001) (22)
Defective synaptic transmission causes disease signs in a mouse model of juvenile neuronal ceroid lipofuscinosis (2017) (22)
Differential blocking effects of the monoclonal anti-GQ1b IgM antibody and alpha-latrotoxin in the absence of complement at the mouse neuromuscular junction (2002) (22)
Eighty three years of the Guillain-Barré syndrome: clinical and immunopathologic aspects, current and future treatments. (1999) (22)
Suppression of P2- T cell line-mediated experimental autoimmune neuritis by interleukin-2 receptor targeted monoclonal antibody ART 18 (1989) (21)
Cerebral abscess in children secondary to esophageal dilatation. (1977) (21)
[Cerebral and spinal MRI examination in patients with clinically isolated syndrome and definite multiple sclerosis]. (2008) (21)
T cell directed immunotherapy of inflammatory demyelination in the peripheral nervous system. Potent suppression of the effector phase of experimental autoimmune neuritis by anti-CD2 antibodies. (1996) (20)
Schwann cells, but not Oligodendrocytes, Depend Strictly on Dynamin 2 Function (2019) (20)
Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide. (1997) (20)
Excitability decreasing central motor plasticity is retained in multiple sclerosis patients (2012) (20)
Impaired salivary gland function reveals autonomic dysfunction in amyotrophic lateral sclerosis (2002) (20)
Diagnostic value of sural nerve biopsy in patients with suspected Borrelia neuropathy (2008) (20)
Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury (2016) (20)
Characterization of early immunological responses in primary cultures of differentially activated human peripheral mononuclear cells. (2001) (20)
Effects of ganglioside administration on experimental autoimmune neuritis induced by peripheral nerve myelin or P2-specific T cell lines (1993) (20)
Histocompatibility antigens and chemical reactivity in autoimmunity. (1987) (20)
Cellular infiltrates in skin and sural nerve of patients with polyneuropathies (2017) (19)
IL-17 production by thymocytes upon CD3 stimulation and costimulation with microbial factors. (2006) (19)
CD8+ T cell help is required for efficient induction of EAE in Lewis rats (2013) (19)
Interferon-beta antibodies: implications for the treatment of MS (2003) (19)
Potential implications of a ciliary neurotrophic factor gene mutation in a german population of patients with motor neuron disease (1998) (19)
[Immunogenetics of myasthenia gravis. Significance of HLA-, complement and Cm gene systems for clinical and immunologic parameters]. (2008) (19)
Magnetic resonance image findings of spinal intramedullary abscess caused by Candida albicans: case report. (1995) (18)
Reversible conduction block in human ischemic neuropathy after ergotamine abuse (1992) (18)
Vasculitis-like neuropathy in amyotrophic lateral sclerosis unresponsive to treatment (2011) (18)
Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis (2010) (18)
Comparative analysis of motoneuron loss and functional deficits in PMN mice: implications for human motoneuron disease (1999) (18)
Nerve biopsy in chronic inflammatory neuropathies: in situ biomarkers (2011) (18)
Hereditary neuromyotonia: a mouse model associated with deficiency or increased gene dosage of the PMP22 gene (1997) (18)
Inhibition of brain macrophage/microglial respiratory chain enzyme activity in experimental autoimmune encephalomyelitis of the Lewis rat (1995) (18)
Influenza vaccination in MS: Absence of T-cell response against white matter proteins (2001) (18)
[Cardiac arrhythmias in Guillain-Barre syndrome. An overview of the diagnosis of a rare but potentially life-threatening complication]. (2001) (18)
The Role of Iron and Nerve Inflammation in Diabetes Mellitus Type 2-Induced Peripheral Neuropathy (2019) (17)
Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis (2002) (17)
[Glucocorticosteroid therapy in optic neuritis and multiple sclerosis. Evidence from clinical studies and practical recommendations]. (2001) (17)
Reduced Rate of Microembolism by Optimized Aortic Cannula Position Does Not Influence Early Postoperative Cognitive Performance in CABG Patients (2003) (17)
Regulation of Fas and FasL expression on rat Schwann cells (2000) (17)
Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease (2007) (17)
Autoimmunity and inflammation in the peripheral nervous system (2002) (16)
Adult-onset mixed myopathy with nemaline rods, minicores, and central cores: a muscle disorder mimicking polymyositis (2004) (16)
T-cell apoptosis in inflammatory neuromuscular disorders associated with human immunodeficiency virus infection. (1999) (16)
[Acetylcholine receptor antibodies in the diagnosis of myasthenia gravis. Study of 406 confirmed cases]. (2008) (16)
Tuftsin stimulates the release of oxygen radicals and thromboxane from macrophages. (1983) (16)
Inclusion body myositis in twins. (1999) (16)
Effects of isoflurane anesthesia on F‐waves in the sciatic nerve of the adult rat (2014) (15)
Music, motor control and the brain (2006) (15)
Effects of mast cell degranulation on blood-nerve barrier permeability and nerve conduction in vivo (1994) (15)
Analysis of the monocyte chemoattractant protein 1 -2518 promoter polymorphism in patients with multiple sclerosis. (2004) (15)
Guillain-Barré syndrome and CIDP (1994) (15)
Proof of genetic heterogeneity in the proximal myotonic myopathy syndrome (PROMM) and its relationship to myotonic dystrophy type 2 (DM2) (2000) (15)
Inflammatory Mechanisms in the Pathophysiology of Diabetic Peripheral Neuropathy (DN)—New Aspects (2021) (15)
Tolerance Induction by Intrathymic Expression of P01 (2004) (15)
Localization of interferon-gamma and Ia-antigen in T cell line-mediated experimental autoimmune encephalomyelitis. (1993) (15)
Effects of myasthenic immunoglobulins and of prednisolone on spontaneous miniature end-plate potentials in mouse diaphragms (1979) (15)
Experimental autoimmune myositis in the Lewis rat: lack of spontaneous T-cell apoptosis and therapeutic response to glucocorticosteroid application (2000) (15)
Modulation of EAE by vaccination with T cell receptor peptides: Vβ8 T cell receptor peptide-specific CD4+ lymphocytes lack direct immunoregulatory activity (1993) (14)
The role of nerve inflammation and exogenous iron load in experimental peripheral diabetic neuropathy (PDN) (2016) (14)
Expression of integrins in experimental autoimmune neuritis and Guillain-Barre syndrome (1998) (14)
Vav1-deficient mice are resistant to MOG-induced experimental autoimmune encephalomyelitis due to impaired antigen priming (2003) (14)
Good recovery after sublethal ethylene glycol intoxication: serial EEG and CT findings (1989) (14)
Tenth Meeting of the European Neurological Society 18–22 June, 2000, Jerusalem, Israël (2000) (14)
Stiff person-syndrome IgG affects presynaptic GABAergic release mechanisms (2015) (13)
Strategies for the modulation of neuroimmunological disease at the level of autoreactive T-lymphocytes (1985) (13)
Miller Fisher syndrome: immunofluorescence and immunoelectron microscopic localization of IgG at the mouse neuromuscular junction (2001) (13)
Multifocal motor neuropathy presenting as chronic progressive proximal leg weakness (2004) (13)
Escalating Immunotherapy with Mitoxantrone in Patients with Very Active Relapsing-Remitting or Progressive Multiple Sclerosis (2000) (13)
[Heart involvement in progressive external ophthalmoplegia (Kearns-Sayre syndrome): electrophysiologic, hemodynamic and morphologic findings]. (1986) (13)
Potential implications of a ciliary neurotrophic factor gene mutation in a German population of patients with motor neuron disease. (1998) (13)
Measles virus‐directed responses of CD4+ T lymphocytes in MS patients and healthy individuals (1993) (13)
Substance P stimulates release of arachidonic acid cyclooxygenation products from primary culture rat astrocytes (1987) (12)
Does Down’s Syndrome Protect against Multiple Sclerosis? (2002) (12)
T lymphocyte recognition sites on peripheral nerve myelin P0 protein (1994) (12)
T cell antigenic and neuritogenic activity of recombinant human peripheral myelin P2 protein (1995) (12)
Chronic inflammatory polyneuritis and neuropathies. (1996) (12)
[The significance of determining antibodies to acetylcholine receptor in myasthenia gravis (author's transl)]. (1979) (12)
[Recommendations of Bavarian Muscle Centers of the German Neuromuscular Disease Society for home ventilation of neuromuscular diseases of adult patients]. (1997) (11)
Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor a subunit ( immunoregulation / autoimmune disease / immunotherapy ) (11)
Mild experimental autoimmune encephalitis as a tool to induce blood–brain barrier dysfunction (2010) (11)
Involvement of the visual pathway in hereditary neuropathy with liability to pressure palsies (2000) (11)
Lipooligosaccharide of Campylobacter jejuni prevents myelin-specific enteral tolerance to autoimmune neuritis—a potential mechanism in Guillain-Barré syndrome? (2005) (11)
The role of dietary non-heme iron load and peripheral nerve inflammation in the development of peripheral neuropathy (PN) in obese non-diabetic leptin-deficient ob/ob mice (2019) (11)
Multifocal brain MRI hypointensities secondary to embolic metal fragments from a mechanical heart valve prosthesis (1998) (11)
Necrotizing myopathy in SJL mice. (1988) (11)
Effector mechanisms in demyelinating neuropathies. (1996) (11)
Role of TNF-alpha in high-dose antigen therapy in experimental autoimmune neuritis: inhibition of TNF-alpha by neutralizing antibodies reduces T-cell apoptosis and prevents liver necrosis. (2000) (11)
Usage of vβ3.3 T‐cell receptor by myelin basic protein‐specific encephalitogenic T‐cell lines in the Lewis rat (1999) (11)
Human monoclonal anti-MAG antibody and anti-Leu 7 recognise shared antigenic determinants in peripheral nerve and spinal cord. (1985) (11)
Pregnancy and delivery of a healthy baby in autoimmune Lambert-Eaton myasthenic syndrome (2006) (10)
Chapter 27 – Experimental Autoimmune Neuritis (2005) (10)
Increased lipocortin-1 (annexin-1) expression in the sciatic nerve of Lewis rats with experimental autoimmune neuritis (1999) (10)
A comparative trial of anti-glycoconjugate antibody assays: IgM antibodies to GM1 (1994) (10)
Glucocorticoid-sensitive hereditary inclusion body myositis (1996) (10)
Analysis of immunoglobulin and T cell receptor gene rearrangements in the thymus of myasthenia gravis patients (1989) (10)
Distribution, tolerability and tissue compatibility of intrathecal tizanidine in the sheep (1998) (9)
Role of therapeutic plasmapheresis in chronic inflammatory demyelinating polyneuropathy. (1990) (9)
Bilateral cerebral emboli monitoring during extracorporeal circulation. (1999) (9)
Efficacy of Polyvalent Human Immunoglobulins in an Animal Model of Neuromyelitis Optica Evoked by Intrathecal Anti-Aquaporin 4 Antibodies (2016) (9)
Immune mechanisms in acute and chronic inflammatory polyneuropathies (1988) (9)
Cerebral Microembolus Generation in Different Extracorporeal Circulation Systems (1999) (9)
Glucocorticosteroids modulate antigen-induced T cell apoptosis in experimental autoimmune neuritis and cause T cell proliferation in situ (2001) (8)
[Myotonic dystrophy (DM/Curschmann-Steinert disease) and proximal myotonic myopathy (PROMM/Ricker syndrome). Myotonic muscle diseases with multisystemic manifestations]. (2001) (8)
Treatment with ciliary neurotrophic factor does not improve regeneration in experimental autoimmune neuritis of the Lewis rat (1996) (8)
The lateral thoracic nerve and the cutaneous maximus muscle—A novel in vivo model system for nerve degeneration and regeneration studies (2012) (8)
Soluble dimeric prion protein ligand activates Adgrg6 receptor but does not rescue early signs of demyelination in PrP-deficient mice (2020) (8)
Ptosis in myasthenia gravis: Extended fatigue and recovery bedside test (2006) (7)
THE TREATMENT OF MYASTHENIA GRAVIS (1952) (7)
Myopathy with abnormal mitochondria, transient low electron transport capacity in the respiratory chain, and absence of energy transduction at sites 1 and 2 in vitro. (1986) (7)
The Gdap 1 knockout mouse mechanistically links redox control to Charcot – Marie – Tooth disease (2014) (7)
Intravenous immunoglobulin for myasthenia gravis. (2008) (7)
F response latency determinations. (1984) (7)
[Follow-up of myasthenia gravis. Results of a longitudinal study of the significance of psychosocial predictors]. (1998) (7)
Shared T‐cell receptor gene usage in experimental allergic neuritis and encephalomyelitis (1993) (7)
Nerve conduction abnormalities and neuromyotonia in genetically engineered mouse models of human hereditary neuropathies. (1999) (7)
Application of the avidin-biotin system for post-embedding cytochemical demonstration of a biotin-labeled IgG tracer. (1986) (7)
Epstein-Barr virus-transformed B cells can present acetylcholine receptor to autologous autoreactive T cells. (1986) (7)
Sarcoid myopathy and mitochondrial respiratory chain defects: clinicopathological, biochemical and molecular biological analyses (1995) (7)
Biomarkers in the diagnosis and therapy of CIDP (2011) (6)
Oral tolerance in experimental autoimmune neuritis (EAN) of the Lewis rat II. Adjuvant effects and bystander suppression in P2 peptide-induced EAN (2001) (6)
Oculomotor signs in Lambert‐Eaton myasthenic syndrome—coincidence with myasthenia gravis (2003) (6)
[Neuromuscular manifestations of HIV-1 and HTLV-I infections]. (2008) (6)
Myasthenia gravis and Lambert-Eaton Myasthenic Syndrome (1994) (6)
Myasthenia Gravis: Pathogenesis and Immunotherapy (2007) (6)
Production and Characterization of Monoclonal Antibodies to the Extracellular Domain of PO (6)
Effects of polyclonal immunoglobulins and other immunomodulatory agents on microglial phagocytosis of apoptotic inflammatory T-cells (2003) (6)
Myasthenia gravis: remission not induced by blocking anti-idiotype antibodies. (1983) (6)
Truncation of the neuritogenic peptide bP2(60–70) results in the generation of altered peptide ligands with the potential to interfere with T cell activation (2002) (6)
“Sporadic” familial amyloidotic polyneuropathy in a German patient with B cell lymphocytic leukaemia (2002) (6)
T-cell receptor Vβ-element expression in peripheral nerves of Lewis rats suffering from experimental autoimmune neuritis (1997) (6)
Plasma-separation in myasthenia gravis: A new method of rapid plasma exchange (1980) (6)
[Plasma exchange treatment in chronic polyneuritis of the Guillain-Barré type. Experiences with 9 personal cases]. (1986) (6)
Human T lymphocytes distinguish bovine from human P2 peripheral myelin protein: Implications for immunological studies on inflammatory demyelinating neuropathies (1994) (6)
Leber´s hereditary optic neuroretinopathy (1993) (5)
Acute Muscular Weakness (1994) (5)
Permanent effector phenotype of neuroantigen-specific T cells acquired in the central nervous system during experimental allergic encephalomyelitis (2006) (5)
[Standardized bicycle ergometry test in mitochondrial myopathies. Indications, interferences and clinical parameters]. (1998) (5)
[Therapy with immunoglobulins in neurologic autoimmune diseases. Indications and mechanism of action]. (1995) (5)
Heat hyperalgesia and nociceptor excitation after application of nerve growth factor (NGF) or inflammatory mediators (1996) (5)
Amyotrophe Lateralsklerose (2010) (5)
Electrophysiological analysis of cutaneous sensory neurons in neonatal wildtype mice and transgenic animals lacking BDNF (1995) (5)
Mice carrying an analogous heterozygous dynamin 2 K562E mutation that causes neuropathy in humans develop predominant characteristics of a primary myopathy (2020) (5)
Nerve Conduction Abnormalities and Neuromyotonia in Genetically Engineered Mouse Models of Human Hereditary Neuropathies (1999) (5)
Multiple exercise-related mononeuropathy with abdominal colic (1983) (5)
Novel SOD1 N86K mutation is associated with a severe phenotype in familial ALS (2007) (5)
Meningioma associated with McCune-Albright syndrome (1999) (5)
Distal‐symmetric focal inflammatory myopathy distinct from focal myositis and polymyositis (2009) (5)
Auto-SCT in severe paraproteinemic neuropathy (2011) (4)
Disorders of Cholinergic Synapses in the Peripheral Nervous System (1988) (4)
[A transferable "myasthenogenic" factor in the serum of patients with myasthenia gravis (author's transl)]. (1976) (4)
Treatment-Induced Neuropathy in Diabetes (TIND)—Developing a Disease Model in Type 1 Diabetic Rats (2021) (4)
Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic (2010) (4)
[Cyclophosphamide in therapy of chronic progressive multiple sclerosis. Critical analysis of current studies]. (1994) (4)
New concepts in immunotherapy. (1984) (4)
sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis - a cross-sectional pilot study (2002) (4)
Ciliary neurotrophic factor (CNTF): physiological and pharmacological effects. (1995) (3)
Persisting rhinorrhoea and headache as the initial symptom of bilateral carotid artery dissection (1999) (3)
Postlumbar puncture headache. (1997) (3)
[Recurrent transverse myelitis. 2 cases and review of the literature]. (1998) (3)
Synergism in the pathogenesis of EAE induced by an MBP-specific T cell line and monoclonal antibodies to Galacto-Cerebroside or to a myelin oligodendroglial glycoprotein (1987) (3)
[Clenbuterol in amyotrophic lateral sclerosis. No indication for a positive effect]. (1999) (3)
[Mitoxantrone (Novantron) in therapy of severe multiple sclerosis. A retrospective study of 15 patients]. (1999) (3)
Quantitative magnetization transfer imaging in human brain by means of a PACE technique. (1999) (3)
B cell responses to the PNS protein P0 in experimental autoimmune neuritis (1995) (3)
Quantitative analysis of energy metabolism in human muscle using SLOOP 31P-MR-spectroscopy. (2002) (3)
Myasthenia gravis: Current State of Knowledge (1981) (3)
α‐Fetoprotein and neonatal transient myasthenia gravis (1984) (3)
Plasmapheresis in chronic demyelinating polyneuropathy. (1992) (3)
Autoimmunity in the peripheral nervous system. (1996) (2)
Sequestration of endogenous NGF in adult rats specifically reduces the sensitivity of nociceptors to heat and bradykinin (1996) (2)
[Immunogenetics of myasthenia gravis]. (1983) (2)
Activation of dissociated IB4 binding dorsal root ganglion (DRG) neurons by ATP and capsaicin (CAPS) (1998) (2)
Oxide Synthase Th 1-Type Cytokines and Inducible Nitric Encephalomyelitis : Rapid Induction of Therapy in Experimental Autoimmune Molecular Mechanisms of High-Dose Antigen (2000) (2)
The effect of noradrenaline on the receptive properties of cutaneous C-fibres in a chronic constriction neuropathy (1993) (2)
Treatment with recombinant human nerve growth factor (rhNGF) normalises the small fibre neuropathy in STZ diabetic rats (1996) (2)
[New aspects of the pathogenesis and therapy of Guillain-Barré syndrome and chronic polyneuritis]. (1990) (2)
Cardiac Involvement in Kearns-Sayre Syndrome (1989) (2)
Current status of plasma exchange in Neurology (1988) (2)
Chapter 25 – Introduction to Immune Reactions in the Peripheral Nervous System (2005) (2)
Intravenous immunoglobulin for myasthenia gravis. (2006) (2)
[Amyotrophic lateral sclerosis: management of bulbar symptoms]. (2010) (2)
alpha-Fetoprotein and neonatal transient myasthenia gravis. (1984) (2)
Persisting rhinorrhea and headache as the initial symptom of bilateral carotid artery dissection. (1999) (2)
The 3rd German-Japanese Joint Workshop. Cell Death in the CNS: Molecules and Programs (1996) (2)
BONE MARROW TRANSFER FROM WILD‐TYPE MICE REVERTS THE BENEFICIAL EFFECT OF GENETICALLY MEDIATED IMMUNE DEFICIENCY IN MYELIN MUTANTS (2002) (2)
[Multiple sclerosis: updates on pathogenesis and treatment: report from the 9th MS Symposium held by the German Multiple Sclerosis Society]. (2011) (2)
Myeloma neuropathy: Clinical and electrophysiological monitoring under plasma exchange therapy (1983) (2)
Can we get rid of neutralizing antibodies against interferon‐β? (2009) (2)
[Comment on the contribution by F. Zipp and K. P. Wandinger. Current recommendations for vaccinations in multiple sclerosis]. (2001) (1)
Dimeric prion protein ligand activates Adgrg6 but does not rescue myelinopathy of PrP-deficient mice (2020) (1)
Analysis of cutaneous afferents in mice carrying targeted mutations of the BDNF gene (1996) (1)
Immune mechanisms in neurological disease (2002) (1)
T-cell receptor V beta-element expression in peripheral nerves of Lewis rats suffering from experimental autoimmune neuritis. (1997) (1)
Modulation of EAE by vaccination with T cell receptor peptides: V beta 8 T cell receptor peptide-specific CD4+ lack direct immunoregulatory activity. (1994) (1)
Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain (1994) (1)
Functional properties of cutaneous unmyelinated afferents in a chronic constriction neuropathy (1993) (1)
Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain (1994) (1)
Focal brain ischemia in mice does not cause electrophysiological signs of critical illness neuropathy (2020) (1)
Differences in Antigen Expression on Normal Thymocytes and on Cells Derived from Hyperplastic Thymi and Thymoma of Myasthenia Gravis Patients (1984) (1)
Kenneth Ricker, MD (1935–2004) (2004) (1)
Augmentation of oxidative and arachidonate metabolism in macrophages by tuftsin (Thr-Lys-Pro-Arg) (1984) (1)
Analysis of mice carrying targeted mutations of the BDNF gene (1994) (1)
Immune Deficiency in Mouse Models for Inherited Peripheral Neuropathies Leads to Improved Myelin Maintenance (2000) (1)
Bacterial expression of a soluble T-cell receptor alpha chain. (1994) (1)
GUILLAIN-BARRÉSYNDROME: PROGNOSIS AND PATHOGENESIS (1988) (1)
Pierson syndrome (2020) (1)
Serum acetylcholine receptor antibodies in diagnosis and therapy monitoring of myasthenia gravis (1980) (1)
4-13-14 Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen species (1997) (1)
[Autoimmune neuropathies--current aspects of immunopathologic diagnostics and therapy]. (2005) (1)
[Active vaccinations in multiple sclerosis]. (1995) (1)
[Hydranencephaly versus spelencephaly--a report of two cases (author's transl)]. (1977) (1)
[Muscle biopsy in progressive external ophthalmoplegia (author's transl)]. (1979) (1)
Disease Management in Multiple Sclerosis (2005) (1)
Inclusion body myositis in twins [6] (multiple letters) (1999) (1)
The immune system in neurologic disease: selected recent developments. (1996) (1)
A practicable method for the analysis of T lymphocyte subsets in CSF lymphopleocytosis (1983) (1)
Clinical implementation of anti-acetylcholine receptor antibodies. (1994) (1)
Adoptive transfer experimental autoimmune encephalitis: evidence for central and peripheral nerve dysfunction (1987) (1)
Humoral or cellular effector mechanisms? (1983) (1)
[Home ventilation in neuromuscular diseases in adults. Presentation of recommendations of the Bavarian Muscle Centers of the DGM]. (1996) (1)
[Immune augmenting therapy as treatment of multiple sclerosis. Warning regarding a potentially toxic alternative treatment method]. (1994) (1)
Long-Term Prognosis of Patients with Thymoma-Associated Myasthenia Gravis (1997) (1)
Myasthenia gravis: new therapeutic strategies. (1988) (1)
Significance of acetylcholine receptor antibody in the diagnosis and therapy monitoring ofMy Asthenia gravis (1980) (1)
Contents Vol. 53, 2005 (2005) (1)
Lambert-Eaton myasthenic syndrome: evaluation of movement performance following drug therapy. (1994) (1)
Letters to the editor (1991) (1)
PROTECTION OF END PLATES BY FAB FRAGMENTS FROM HUMAN MYASTHENIC IGG IN THE MOUSE TRANSFER MODEL (1981) (1)
Complex immunoregulatory events during pregnancy may explain reduced relapse rate in multiple sclerosis (1998) (1)
154 Specific subtypes of cutaneous mechanoreceptors require neurotrophin-3 following peripheral target innervation (1996) (1)
[Treatment of relapsing-remitting multiple sclerosis with recombinant interferon-beta preparations]. (2001) (1)
Soluble VCAM-1 Release Indicates Inflammatory Blood-Brain Barrier Pathology and Further Modulates Adhesion (2004) (1)
[New aspects in the diagnosis of herpes simplex virus encephalitis--case reports and virologic findings]. (1992) (0)
11th meeting of the peripheral nerve study group (PNSG) “lostergut Jakobsberg”, Boppard, Germany 29 July–1 August 1993 (1995) (0)
[Paraneoplastic syndromes of the nervous system]. (1990) (0)
Peripheral neuropathy orchestrated by nonneural-specific lymphocytes (1994) (0)
[The role of the immune system in hereditary demyelinating neuropathies]. (2005) (0)
Efficacy of therapy in juvenile myasthenia gravis (M.G.) (1991) (0)
[Alopecia areata and EEG-changes]. (1974) (0)
Author response: Defective synaptic transmission causes disease signs in a mouse model of juvenile neuronal ceroid lipofuscinosis (2017) (0)
DRUG TARGETING BY LONG-CIRCULATING LIPOSOMAL GLUCOCORTICOIDS INCREASES THERAPEUTIC EFFICACY IN A MODEL OF MULTIPLE SCLEROSIS CHAPTER (2003) (0)
Reactive nitrogen intermediates: Effector molecules of immune‐mediated inflammatory nervous system disorders? (1993) (0)
5-25-07 T cell activation and homing in adoptive transfer experimental autoimmune neuritis (AT-EAN) (1997) (0)
Subject Index Vol. 53, 2005 (2005) (0)
Role of autophagy in adipose tissue and in peripheral nervous system in diabetes type 2, obesity and metabolic syndrome (2016) (0)
Immune-mediated peripheral nerve disorders (1991) (0)
Letters to the Editor (1988) (0)
Book Review / Announcement (2002) (0)
[Periarticular ossification following severe brain injury]. (1977) (0)
[A transferable "Myasthenogenic" factor in the serum of patients with myasthenia gravis.]. (1976) (0)
5-29-10 Mitochondrial dysfunction with MERRF point-mutation in nerve and muscle tissue of a patient with multiple symmetric lipomatosis (1997) (0)
Anti-nicotinic receptor autoimmunity in myasthenia gravis. Establishment of specific T-helper cell lines and identification of sensitizing epitopes on the alpha-subunit. (1988) (0)
Effective Treatment With Intracutaneous Botulinum Toxin (2017) (0)
This information is current as Encephalomyelitis of SJL Mice Experimental Autoimmune 151 Peptide-Induced - Protein 139 IL-17-Producing CD4 Cells in Proteolipid Kinetics and Organ Distribution of (2017) (0)
Author response: Schwann cells, but not Oligodendrocytes, Depend Strictly on Dynamin 2 Function (2018) (0)
Aetiology of small-and mixed-fiber neuropathy (2006) (0)
Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury (2016) (0)
Book reviews – Announcements (2001) (0)
In Memoriam: Daniel B. Drachman (2022) (0)
MRI changes of nerve and muscle after nerve lesions: Correlation with electromyography and histology (2005) (0)
Stimulation of autoimmune helper T-lymphocytes from myasthenia gravis patients with synthetic peptides of the acetylcholine receptor alpha subunit (1987) (0)
Fisher syndrome : immunofluorescence and immunoelectron microscopic localization of IgG at the mouse neuromuscular junction (0)
Encephalomyelitis of SJL Mice Experimental Autoimmune 151 Peptide-Induced − Protein 139 IL-17-Producing CD 4 Cells in Proteolipid Kinetics and Organ Distribution of Tary-Lehmann and (2007) (0)
T cell receptor Vβ sequence analysis in target tissue suggests contribution of myelin basic protein autoreactivity to experimental allergic neuritis (1994) (0)
[Clinical, morphological and biochemical findings in the Kearns-Sayre syndrome]. (1983) (0)
Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, and Axonal Degeneration and Regeneration (2008) (0)
Reversible, combined pre- and postsynaptic blockade of neuromuscular transmission by anti-GQ1b antibodies from patients with Miller Fisher syndrome (MFS) (1999) (0)
Expression of P0 Tolerance Induction by Intrathymic (2004) (0)
[Disorders of receptor function as a pathogenetic principle in myasthenia gravis]. (1988) (0)
Localization of Interferon-y and la-Antigen in T Cell Line-Mediated Experimental Autoimmune Encephalomyelitis (2007) (0)
Letters to the editor (1983) (0)
Communications of the European Neurological Society (2001) (0)
Some Thoughts from Your Publisher (2002) (0)
Different monoclonal anti-ganglioside antibodies show distinct effects on presynaptic transmitter release and calcium influx (2006) (0)
ENS News (1999) (0)
19Syndrome, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, and Axonal Degeneration and Regeneration (2008) (0)
[Therapy of acute polyradiculoneuritis (Guillain-Barré syndrome)]. (1994) (0)
[Early diagnosis of multiple sclerosis]. (2000) (0)
T-cell apoptosis in the nervous system and therapeutic implications (2001) (0)
Letters to the editor (0)
Myasthene Krise (2003) (0)
Morphological And Electrophysiological Signs Of Dysmyelination In Transgenic Mice Expressing CMT1B (MPZ DELSer34) or DSS (MPZ Ser34Cys) Mutations (2001) (0)
Selective Adsorption Therapy in Myasthenia Gravis (1987) (0)
Surgical and neurological outcome of thymectomy for myasthenia gravis (2008) (0)
Neurofibromatous neuropathy. (1991) (0)
A reliable method for immunocytochemical characterization of CSF cells (1987) (0)
Sequence and diversity of rat T-cell receptor Tcra V8 gene segments (2004) (0)
Functional predictors of treatment induced diabetic neuropathy (TIND): a prospective pilot study using clinical and neurophysiological functional tests (2021) (0)
Eleventh meeting of The European Neurological Society21–25 April, 2001, Paris, France (2001) (0)
Correction: Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells (2010) (0)
[Distrubances in glucose metabolism during diphenyhydantoin treatment in childhood]. (1975) (0)
Abstracts Second Congress of the European Society for Clinical Neuropharmacology (1995) (0)
Suppression of P2-T cell-line mediated experimental autoimmune neuritis by interleukin 2 — Receptor blockade (1987) (0)
Myasthenia gravis : First European Conference on Myasthenia Gravis, Maastricht, June 15-16, 1987 (1988) (0)
Changes of the Blood-Nerve Barrier During Nerve Regeneration in the Mouse (1987) (0)
The thymic remnant in the pathogenesis of thymoma associated myasthenia gravis (MG) (1991) (0)
Surgical outcome and survival after thymomectomy (2008) (0)
Mitochondrial dysfunction with MERRF point-mutation in nerve and mucle tissue of a patient with multiple symmetric lipomatosis (1997) (0)
3-24-08 Apoptotic cell death of myoblasts by oxidative stress and nitric oxide (1997) (0)
Immunohistochemical Demonstration of IgG and Fab Fragments at Motor Endplates of Passively Transferred Mice (1981) (0)
Letters to the editor (1984) (0)
Administration of nitric oxide (NO) synthase inhibitors in experimental autoimmune encephalomyelitis (EAE) (1995) (0)
IMMUNOGLOBULIN G FROM PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) AFFECTS PRESYNAPTIC TRANSMITTER RELEASE AND CALCIUM INFLUX (2009) (0)
Abstracts of the Symposia (2006) (0)
Hydrophobic binding properties of AChR-antibodies: aspects for therapy and pathomechanism in myasthenia gravis (1989) (0)
Cellular immunity in inflammatory autoimmune neuropathies. (2002) (0)
Suppression and Treatment of EAN by Novel Antiinflammatory Agents Acting on Macrophages (1987) (0)
Effect of Intravenous Diphenylhydantoin on Glucose Tolerance and Insulin Response in Children (1975) (0)
Peripheral Nerve Study Group, in Boppard, Germany, July 29th to August 1, 1993. (1994) (0)
Quantitative magnetization transfer imaging in relapsing multiple sclerosis. (2000) (0)
[Retinal dystrophy in mitochondriopathy]. (1986) (0)
[Analysis of surface markers on cerebrospinal fluid-producing cells. Contribution to the differential diagnosis of intrathecal lymphomas]. (1984) (0)
Cancer Incidence in 677 Mitoxantrone-Treated People with Multiple Sclerosis: A Retrospective German Single Center Cohort Study (P01.175) (2013) (0)
Antibodies against the amphiphysin sh-3 domain mediate reduced gabaergic motor inhibition and anxiety of stiff person syndrome (2008) (0)
Professor Georg Becker, MD (1961–2003) (2003) (0)
Focal brain ischemia in mice does not cause electrophysiological signs of critical illness neuropathy (2020) (0)
[Successful treatment of multiple sclerosis with beta-interferon]. (1999) (0)
Postnatal survival of Merkel cells depends on the low affinity neurotrophin receptor p75. (1998) (0)
Analysis of sensory neurons in transgenic mice carrying targeted mutations of the p75 gene (1996) (0)
Single unit recordings from chick cutaneous sensory neurons in vitro (1994) (0)
Temporary reversal of nerve and muscle dysfunction by serial electrical stimulation in critical illness neuromyopathy (2022) (0)
Oral session 39 — Growth factors (2005) (0)
Severely decreased skin innervation in mice lacking the low affinity neurotrophin receptor (1996) (0)
Excitability decreasing central motor plasticity and functional role of primary motor cortex are retained in multiple sclerosis patients (2012) (0)
Abnormal functional properties of nociceptive afferents in neuropathic pain (1993) (0)
Effects of BDNF and NGF on cytokine expression in immune cells (2001) (0)
Targeted rescue of synaptic plasticity improves cognitive decline after severe systemic inflammation (2021) (0)
Interferon-b induces release of soluble adhesion molecules from human cerebral endothelial cells (1998) (0)
Effect of tetrodotoxin on cutaneous afferent fibers in adult rat in the skin-nerve in vitro preparation (1996) (0)
Short-term plasticity is not compromised in multiple sclerosis patients (2008) (0)
Characterization of cutaneous sensory neurones in BDNF transgenic animals (1995) (0)
Nerve growth factor (NGF) is required for the function of unmyelinated nociceptive afferents (1995) (0)
NGF produces heat hyperalgesia, an excitation of nociceptors and sensitization to heat (1996) (0)
[Therapy of MS symptoms. Here also are guidelines necessary]. (2004) (0)
[Oral, low-dosage methotrexate in chronic progressive multiple sclerosis. A preliminary critical analysis]. (1995) (0)
Plasma exchange for generalised myasthenia gravis (Review) (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Klaus Viktor Toyka?

Klaus Viktor Toyka is affiliated with the following schools:

Klaus Viktor Toyka's Academic­Influence.com Rankings

Why Is Klaus Viktor Toyka Influential?

Klaus Viktor Toyka's Published Works

Published Works

What Schools Are Affiliated With Klaus Viktor Toyka?

Klaus Viktor Toyka's AcademicInfluence.com Rankings